Why we just sold Zip and bought Pro Medicus (ASX:PME) shares: fundie

Why sell-off Zip for Pro Medicus?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Pro Medicus share price has slipped more than 4% at the time of writing while Zip is down almost 3%
  • An investment head at Abrdn has revealed the reason for a pivot from Zip to Pro Medicus 
  • Pro Medicus reported a nearly 53% surge in its net profit after tax in its half-yearly results 

A high-level funds manager has divulged her fund's strategy of offloading Zip Co Ltd (ASX: Z1P) shares and buying Pro Medicus Ltd (ASX: PME) instead.

The Pro Medicus share price is down 4.48% at the time of writing at $44.10, after falling as low as $43.59 earlier today. Meanwhile, Zip shares are around 2.62% lower.

By comparison, the S&P/ASX 200 Index (ASX: XJO) is down around 1% so far today.

Let's take a look at what the Australian head of one global investment firm had to say.

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop.

Image source: Getty Images

Why Pro Medicus instead of Zip?

Amid interest rate speculation, the Russian invasion of Ukraine, and the east coast floods, one investment head has outlined reasons for a shift towards a growth share like Pro Medicus over buy now, pay later (BNPL) share Zip.

Speaking to LiveWire, Abrdn Australian equities head Michelle Lopez explained her fund's major portfolio shift with its move to a growth share like Pro Medicus.

So we pivoted out of a company, for example, Zip, that had a very long runway to turn profitable. And we recycled that capital into a higher quality growth name, such as a Pro Medicus, that again, got hit very hard. 

But, A, it's profitable, B, it's got incredibly strong margins. It's an industry leader. It's got cash on the balance sheet. And again, we felt the valuation had come off a long way. So it was just being a lot more discriminate in quality growth versus lower quality growth.

In its half-yearly results, Pro Medicus reported net profit surged by 52.7% and revenue increased by 40%. The company's shares gained 3.6% on 16 February, the day these figures were released.

Lopez also shared her insight into the latest reporting season, describing it as "turbulent". She added:

We've had rising inflation, we've got interest rates and expectations of hikes coming through, and we've got geopolitical tensions escalating. I felt it was a case of "shoot first and ask questions later" this reporting season.

Particularly for companies that had either very high valuations or operating leverage that was expected to come through that didn't, they're the ones that really got hit quite hard.

The Pro Medicus share price has sunk 26% in the past six months while the Zip share price has tanked 76% over the same time frame.

Share price recap

The Pro Medicus share price has held steady during the past 12 months, gaining a modest 0.75%, while Zip shares have shed around 83%.

For comparison, the benchmark ASX 200 index has returned about 5% over the past year.

Year to date, Pro Medicus shares have dived nearly 30%, while Zip shares have slumped around 62%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. and ZIPCOLTD FPO. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »